Welcome to our dedicated page for LXRP news (Ticker: LXRP), a resource for investors and traders seeking the latest updates and insights on LXRP stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect LXRP's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of LXRP's position in the market.
Lexaria Bioscience Corp. (OTCQX:LXRP) has announced significant advancements in its antiviral research initiatives. The company has received conditional ethics board approval for a pilot study evaluating its DehydraTECH technology in human antiviral drug delivery, pending further regulatory approval. Additionally, Lexaria launched a rodent study to assess the pharmacokinetic benefits of DehydraTECH with drugs targeting COVID-19. Results from this rodent study are expected in December 2020. The company aims to improve the bioavailability of antiviral drugs, potentially enhancing treatment access and effectiveness.
Lexaria Bioscience Corp. (OTCQX:LXRP) announced on September 23, 2020, that it received commitments for approximately 4.4 million CBD servings of its patented DehydraTECH-enabled CBD powders, set for processing in fiscal Q1 2021. Verbal requests indicate potential orders totaling 56 million servings for the remainder of 2021. This is a notable increase from 1.2 million servings processed in fiscal Q4 2020. CEO Chris Bunka highlighted the growing traction of DehydraTECH in the US market. Lexaria maintains adequate resources to meet the anticipated demand.
Lexaria Bioscience Corp. (OTCQX:LXRP) has been granted U.S. Patent No. 10,756,180 for its DehydraTECH technology, enhancing the delivery of cannabinoids, nicotine, and NSAIDs in beverage formats. This patent marks a significant expansion of Lexaria's intellectual property portfolio, which now includes 17 granted patents globally. The company is optimistic about future patent approvals in various countries, supporting its growth in drug delivery solutions. With a focus on improving bio-absorption and reducing onset times for active ingredients, Lexaria aims to transform ingestible product formats.
Lexaria Bioscience Corp. (LXRP) is supporting the growth of its licensee, Boldt Runners Corporation, which owns the Cannadips CBD brand. Boldt Runners is poised for significant growth due to new executive appointments, financing, and expanded sales channels. The recent appointment of Peter Diatelevi as CEO is expected to enhance Cannadips CBD's market presence. A new state-of-the-art manufacturing facility has been completed, allowing for increased production capacity and the implementation of Lexaria's DehydraTECH technology. This partnership aims to boost sales volumes significantly in the next year.
Lexaria Bioscience Corp. (OTCQX:LXRP) has entered into a research and development agreement with British American Tobacco (BAT) to explore the use of Lexaria's drug delivery technology in nicotine products. BAT will fund the R&D efforts, which are set to conclude in six months, with potential extensions. The agreement does not involve oral nicotine product development in North America due to an existing partnership with a US tobacco company. Lexaria's proprietary technology, DehydraTECH, enhances bio-absorption and reduces onset time for various active ingredients.